SPECIFICITIES OF THE SUBSET PROFILE OF PERIPHERAL BLOOD IN PATIENTS WITH GLIOBLASTOMA: PATHOGENETIC AND CLINICAL ASSESSMENTS

Abstract. In glioblastoma (GB), it is necessary to take into consideration GB-associated secondary immunodeficiency (SID), so-called syndrome of tumor-associated SID (STASID). Cell subsets having effector and regulatory functions, play an important role in developing STASID, and their proportions in patients with different forms of GB can be of pathogenetic importance and have clinical value for treatment and rehabilitation scheduling as well. The most pathogenically and clinically important features of cell subsets profile of peripheral blood were analyzed in patients with different clinical and morphological types of GB. The patients were divided into three groups, i.e., groups I and II were formed by patients with STASID (marked and slightly marked SID, accordingly); group III – patients with SIDTAS (tumor-associated autoimmune syndrome, associated with SID). Marked suppression of cell immunity is typical of group I - imbalance in T-lymphocytes, in a number of specific subsets, and in subsets clusters, as well as disproportions in the immunoregulatory indexes. In group II, the subset profiles of blood were slightly different from the norm. In patients with SIDTAS, activation of cell immunity was evident, forming SID with signs of autoimmune syndrome, affecting effector and regulatory chains of immunity, and influencing the severity and forecast of the disease. Specific features of the immune status in patients with GB identified can be resulted from different clinicalmorphological types of the tumor; the latter are to be considered in differential diagnostics of clinical course of GB and in scheduling of clinical-immunological efficient anti-tumor pharmacotherapy in pre- and postoperative periods.

1. Барышников А.Ю. Моноклональные антитела серии ИКО к дифференцировочным антигенам лимфоцитов человека // Гематол. трансфузиол.– 1990.– № 8.– С. 4.

2. Голанов А.В. Глиобластомы больших полушарий головного мозга: результаты комбинированого лечения и факторы, влияющие на апоптоз // Автореф. дис. ... д-ра мед. наук.- М., 1999.

3. Коршунов А.Г., Сычева Р.В., Голанов А.В. Иммуногистохимическое изучения апоптоза в глиобластомах больших полушарий головного мозга // Архив патологии.- 1998.-N.60- С.23-27.

4. Хонина НЛ., Центнер М.И., Леплина О.Ю, Тихонова М.А., Ступак В.В., Никонов С.Д., Черных Е.Р., Останин А.А. Характеристика и механизмы иммунных нарушений у больных со злокачественными опухолями головного мозга // Вопросы онкологии.– 2002. –Т. 48- №2. С196-201.

5. Чумаков В.А., Качков И.А., Благовещенский С.В., Пронина О.А., Зубова Ю.Е., Гнучев Н.В., Кузнецов В.П., Сучков С.В. Типичный и атипичный варианты иммунологического ответа у больных с глиобластомой // Журнал “Цитокины и воспаление” – М. – 2002. – Т.1 – № 2. – С. 83.

6. Чумаков В.А., Биктимиров Р.Г., Качков И.А., Пронина О.А., Гнучев Н.В., Кузнецов В.П., Голанов А.В., СучковС.В. Серологические особенности у больных с глиобластомой // Материалы III-го съезда нейрохирургов России. С.-П., 2002, 4-8 июня, С. 172-173.

7. Barber D.F., Burshtyn D.N., Faure M., Peterson M., Rajagopalan S., Renard V., Sandusky M., Stebbins C.C., Wagtmann N., Watzl C. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158) // Immunol Rev.- 2001.- Vol.181-P.223-233.

8. Bofill M., Borthwick N.J. CD38 in health and disease // Chem Immunol.– 2000.-Vol.75.-P.218-234.

9. Bohbot A., Feugeas O., Cuillerot J.M., Grosse A., Rusciani I., Faradji A., Oberling F. Peripheral blood CD34+ cells: method of purification and ex vivo expansion // Nouv Rev Fr Hematol. - 1995.-Vol.37.- P.359-365.

10. Boyum A., Lovhaug D., Tresland L., Nordlie E.M. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality // Scand J Immunol.- 1991.-Vol.34.-P697-712.

11. Cabanas C., Sanchez-Madrid F. CD18 (leukocyte integrin beta2 subunit) // J Biol Regul Homeost Agents.- 1999.-Vol.13.-P.137-139.

12. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., Caligiuri M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset // Blood.– 2001.-Vol.97.-P.3146-3151.

13. Deininger M.H., Meyermann R., Schluesener H.J. Expression and release of CD14 in astrocytic brain tumors // Neuropathol (Berl).– 2003.-Vol.106.-P.271-277.

14. Deterre P., Berthelier V., Bauvois B., Dalloul A., Schuber F., Lund F. CD38 in T- and B-cell functions // Chem Immunol.– 2000.-Vol.75.-P.146-168.

15. Dix A.R., Brooks W.H., Roszman T.L., Morford L.A. Immune defects observed in patients with primary malignant brain tumors // J Neuroimmunol.– 1999.- Vol.100.-P.216-232.

16. Dustin M.L., Bivona T.G., Philips M.R. Membranes as messengers in T cell adhesion signaling // Nat Immunol.- 2004.-Vol.5.-P.363-372.

17. Federoff S., Hao C. Origin of microglia and their regulation by astroglia // Adv Exp Med Biol.- 1991.- Vol.296.-P.135-142.

18. Fontana A., Kristensen F., Dubs R., Gemsa D., Weber E. Production of prostaglandin E and an inter-leukin-1 like factor by cultured astrocytes and C6 glioma cells // J Immunol.– 1982.-Vol.129.-P.2413-2419.

19. Fries G., Perneczky A., Kempski О. Glioblastoma-associated circulating monocytes and the release of epidermal growth factor // J. Neurosurg.— 1996.—Vol. 85.-P. 642-647.

20. Hagel C., Park S.H., Puchner M.J., Stavrou D. CD44 expression and tumour cell density correlate with response to tamoxifen/carboplatin chemotherapy in glioblastomas // J Neurooncol.- 2004.-Vol.66.-2.-P.139-146.

21. Herreman G., Godeau P., Cabane J., Acar J.F., Digeon M., Bach J.F. Circulating immuns complexes and infections endocarditis. 64 cases // Ann Med Interne (Paris).- 1978.-Vol.129.-P.387-397.

22. Hunter C.A., Lieberman L.A., Mason N., Pepper M., Sague S.L., Tato C., Zediak V. Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma // Immunol Res.- 2003.-Vol.27.-P.331-340.

23. Kanda T., Yokoyama T., Ohshima S., Yuasa K., Watanabe T., Suzuki T., Murata K. T-lymphocyte subsets as noninvasive markers of cardiomyopathy // Clin Cardiol.- 1990.-Vol.13.-P.617-622.

24. Kleihues P.,Cavenee W.K. eds. Pathology & genetics of tumors of the nervous system. World Health Organisaition classification of tumours. Lyon, France: IARC Press, 2000.

25. Liu Y.J., Kanzler H., Soumelis V., Gilliet M. Dendritic cell lineage, plasticity and cross-regulation // NatImmunol.- 2001.-Vol.2.-P.585-589.

26. Lowe J., MacLennan K.A., Powe D.G., Pound J.D., Palmer J.B. Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells // J Pathol.- 1989.-Vol.159.-P.143-149.

27. Makrigiannis A.P., Anderson S.K. Regulation of natural killer cell function // Cancer Biol Ther.- 2003.- Vol.2.-P.610-616.

28. Menage P., Thibault G., Lebranchu Y., Jan M., Bardos P. Deficiency of CD4+CD45RA+ lymphocytes in patients with glioblastoma multiforme // Eur J Med.- 1992.-Vol.1.-P.362-364.

29. Metelitsa L.S. Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells // Clin Immunol.- 2004.-Vol.110.-P.267-276.

30. Naot D., Sionov R.V., Ish-Shalom D. CD44: structure, function, and association with the malignant process // Adv Cancer Res.- 1997.- Vol.71.-P.241-319.

31. Nicholson I.C. CD62L (L-selectin) // J. Biol. Regul Homeost Agents.-2002.-Vol.16.-P.144-146.

32. Resnick D.K., Resnick N.M., Welch W.C., Cooper D.L. Differential expressions of CD44 variants in tumors affecting the central nervous system // Mol Diagn -1999.-Vol.4.-P.219-232.

33. Romagnani S. Biology of human TH1 and TH2 cells // J Clin Immunol.– 1995.-Vol.15.-P.121-129.

34. Senner V., Sturm A., Baur I., Schrell U.H., Distel L., Paulus W. CD24 promotes invasion of glioma cells in vivo // J Neuropathol Exp Neurol.- 1999.-Vol.58.-P.795-802.

35. Sivori S., Parolini S., Marcenaro E., Castriconi R., Pende D., Millo R., Moretta A. Involvement of natural cytotoxicity receptors in human natural killer cell mediated lysis of neuroblastoma and glioblastoma cell lines // J Neuroimmunol.– 2000.-Vol.107.-P.220-225.

36. Tada M., Karita M., Yanai H., Okita K. Application and limitation of endoscopic polypectomy in stomach polyps // Nippon Naika Gakkai Zasshi.- 1992.-Vol.81.-P.666-672.

37. Takamoto T., Hori Y., Yokoyama M.M., Koga Y., Toshima H. Lymphocyte subsets in patients with dilated cardiomyopathy and perimyocarditis // J Clin Lab Immunol.- 1986.-Vol.19.-P.113-116.

38. Tarazona R., DelaRosa O., Alonso C., Ostos B., Espejo J., Pena J., Solana R. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells // Mech Ageing Dev.- 2000.-Vol.121.-P.77-88.

39. Toba K., Koike T., Shibata A., Hashimoto S., Takahashi M., Masuko M., Azegami T., Takahashi H., Aizawa Y. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils // Cytometry.- 1999.-Vol.35.-P.249-259.

40. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity // Immunol Rev.- 2002.-Vol.188.-P.122-135.

41. Tysnes B.B., Mahesparan R. Biological mechanisms of glioma invasion and potential therapeutic targets // J Neurooncol.- 2001.-Vol.53.-P.129-147.

42. Ware C.F. APRIL and BAFF Connect Autoimmunity and Cancer // J.Exp.Med.- 2000.-Vol.192.- P.35-37.

43. Weller M., Kleihues P., Dichgans J., Ohgaki H. CD95 ligand: lethal weapon against malignant glioma? // Brain Pathol.- 1998.-Vol.8.-P.285-293.

44. Willmann K., Dunne J.F. A flow cytometric immune function assay for human peripheral blood dendritic cells // J Leukoc Biol.- 2000.-Vol.67.-P.536-544.

45. Wintterle S., Schreiner B., Mitsdoerffer M., Schneider D., Chen L., Meyermann R., Weller M., Wiendl H. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis // Cancer Res.- 2003.-Vol.63.-P.7462-7467.

46. Wischhusen J., Jung G., Radovanovic I., Beier C., Steinbach J.P., Rimner A., Huang H., Schulz J.B., Ohgaki H., Aguzzi A., Rammensee H.G., Weller M. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma // Cancer Res.- 2002.-Vol.62.- P.2592-2599.

47. Yasuda M., Nakano K., Yasumoto K., Tanaka Y. CD44: functional relevance to inflammation and malignancy // Histol Histopathol.- 2002.-Vol.17.-P.945-950.

48. Yu S.Z., Zhang J.Q., Lu G.H. An immunohis-tochemical study of Ki-67 expression of brain tumor cells and mononuclear cell subsets infiltrating these tumors // Zhonghua Bing Li Xue Za Zhi.- 1994.-Vol. 23.-P.267-269.

49. Zou J.P., Morford L.A., Chougnet C., Dix A.R., Brooks A.G., Torres N., Shuman J.D., Coligan J.E., Brooks W.H., Roszman T.L., Shearer G.M. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and sur-face markers // J. Immunol.—1999.—Vol. 162.—P. 4882-4892.